# **HLDA9 ANTIBODY VALIDATION FILE**

## **ANTIBODY INFORMATION**

Antibody Name: DJR1

Specificity: Human CD261

Antibody species: Mouse

**Ig Isotype:** IgG1/k

Immunogen:

Epitope recognized: Extracellular domain

Submitter: eBioscience


### **INFORMATION FOR CONFIRMATION OF SPECIFICITY:**

Expression on transfected COS: positive. (Fig. 1A)

Expression on the cell- surface of cell line: positive with B cell leukemia line Ramos. (Fig. 1B)

Expression on cell- surface of normal cell: positive with monocytes. (Fig. 1C)

# Figure 1



Reactivity of CD261 with cell lines

	Cell lines	CD261
EBV-transformed B cells	CESS	+++
Burkitt lymphoma B cell lines	Raji	+++
	Daudi	+
	Namalwa	+
	Ramos	++++
Multiple myeloma	RPMI8226	++
T cell leukemia	Jurkat	+++
	HSB2	+
NK cell leukemia	YT	+
Myeloid leukemia	HL-60	+
	K-562	+
	U-937	+++

# Reactivity of CD261 with PBL

Lymphocytes	-
Granulocytes	-
Monocytes	+

## **INFORMATION PROVIDED BY SUBMITTER**

#### **Publications:**

Ishiyama k, Ohdan H, Mitsuta H, Arihiro k, Asahara T. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology. 2006;43:362-72.

Earel JK Jr, Vanoosten RL, Griffith TS. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res. 2006;66:499-507.

Zang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res. 1999;59:2747-53

### **Patents:**

#### Licensed to a company and which one:

Was it evaluated in a previous workshop? No